“We’ll Go Directly to Aurora Shareholders — And We’ll Win”: Boris Jordan Says Curaleaf Has a Walk-Away Price

Boris Jordan says Curaleaf is prepared to take its bid for Aurora Cannabis directly to shareholders if management rejects the offer. But his confidence comes with a limit: Curaleaf will not chase Aurora at any price.

Asked during an exclusive IgniteIt interview what Curaleaf would do if Aurora says no, Jordan was unequivocal.

“We’re going to go directly to shareholders and we’ll win.”

Jordan argued that Curaleaf’s operating performance gives it a compelling case to make directly to Aurora investors and introduced an equally important constraint.

“Could someone come in and bid more? Yes,” Jordan said. “And is there a price at which I would walk away? Absolutely.”

“I’m very price sensitive,” he added. “I’m only going to do this deal at a price that I think is interesting to Curaleaf.”

Jordan Wants This Done Fast

For Jordan, the biggest risk is not financing or integration. It is time.

“I think the biggest risk is that it gets drawn out longer than it needs to,” he said.

Curaleaf wants to close the transaction by year-end or early January, allowing Aurora to operate as part of its international portfolio for most of 2027.

Jordan said Aurora should consider other alternatives, including potentially finding a buyer willing to pay more.

But he argues that shareholders should consider more than the headline price, since Curaleaf’s proposal is primarily stock.

“It’s not just about the money,” Jordan said. “It’s about who’s the better steward of the capital and where this asset is going to make more money for shareholders.”

The Pitch to Aurora Shareholders

Jordan said approximately 80% of Curaleaf’s consideration would be paid in stock, giving Aurora shareholders exposure to the combined company rather than simply cashing them out.

His pitch rests partly on U.S. cannabis reform.

Jordan believes Curaleaf could benefit significantly from federal rescheduling and a resulting revaluation of U.S. cannabis equities. Aurora shareholders receiving Curaleaf shares, he argues, would participate in that potential upside.

“The faster they get Curaleaf stock, the more chance they have to earn an outsized return,” Jordan said.

It is an aggressive argument, particularly because the regulatory catalyst Jordan is counting on has not yet occurred. But it clarifies Curaleaf’s message to Aurora investors: judge the offer not only by what Aurora is worth today, but by what their ownership in the combined company could be worth later.

And if another bidder values Aurora considerably higher?

Jordan appears prepared to let them have it.

“Is there someone that can come in and make a bid that’s much higher than what we are prepared to make? Maybe,” he said. “And then we’ll evaluate that and make a decision.”

Curaleaf wants Aurora. Jordan sounds confident he can convince its shareholders why.

Next in the series: Jordan lays out his timeline for U.S. cannabis rescheduling, Curaleaf’s expected 2027 uplisting, the hemp ban in the U.S., and what he believes federal reform could trigger across the industry.

Stay tuned. Stay ignited.